Search Results 811-820 of 17385 for alopecia
... alopecia, oxaliplatin-related neuropathy, asymptomatic electrolyte abnormalities, and other non-clinically significant adverse events. - Any of the ...
Patients with Grade 2 neuropathy or Grade 2 alopecia are eligible. Active idiopathic thrombocytopenic purpura. Active central nervous system (CNS) ...
... alopecia; Cardiac conditions as follows: Uncontrolled hypertension (blood pressure [BP] >=150/95 mmHg despite medical therapy); Left ventricular ejection ...
... alopecia) and/or in whom ≥25% of the bone marrow (Ellis, 1961) was irradiated. Patient has had major surgery within 14 days prior to starting study drug or ...
... alopecia. If subject received major surgery or radiation therapy of > 30 Gy, must have recovered from the toxicity and/or complications from the ...
With the exception of alopecia, and CTCAE Grade 2 neuropathy, any unresolved toxicities from prior therapy > Grade 1 at the time of starting study treatment.
Inclusion Criteria: Patients with Barrett's Esophagus (BE) or Esophageal Adenocarcinoma (EAC) that are planned for Endoscopic Submucosal Dissection (ESD) ...
... alopecia prior to initiating protocol therapy. Bisphosphonate therapy and RANKL inhibitors are not considered anti-cancer therapy. Inadequate recovery from ...
Failure to recover to ≤Grade 1 from acute, reversible effects of prior chemotherapy, excluding alopecia regardless of interval since last treatment. NOTE ...
Recovery to Grade 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administration. Satisfactory laboratory ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.